• AFT Pharmaceuticals are a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter, prescription and hospital.

    AFT's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs.

  • Maxigesic global growth continues

    AFT Pharmaceuticals reported a strong lift in revenue and earnings for the 2020 financial year following sales growth and cost control in its diversified Australasian medicines business and growing international sales of its patented Maxigesic pain relief drug.

    To view the announcement please click here.

  • NZX

    Shares in AFT Pharmaceuticals Limited (“AFT”), began trading on the NZX Main Board and ASX on 22 December 2015, following the successful IPO that raised $35.6 million through the issue and sale of New and existing shares.

    To view the announcements please click here.

Share Price & Graph

4.76
-0.04 -0.8%
12:17PM 28/11/2020
4.51
0.00 0.0%
10:02AM 27/11/2020
View more

Announcements

 

Key Dates

Annual Meeting 12 August 2020
Financial Half Year End 30 September 2020
Half Year Results Announcement November 2020
Financial Year End March 2021
 
 

Latest Investor
Presentation

View our latest presentations
 

Sign up for a request to be invited onto
our email subscribers database.

Subscribe